Chemoinformaics analysis of 6,6,7-Trimethyl-octane-2,5-dione
| Molecular Weight | 184.279 | nRot | 5 |
| Heavy Atom Molecular Weight | 164.119 | nRig | 2 |
| Exact Molecular Weight | 184.146 | nRing | 0 |
| Solubility: LogS | -1.695 | nHRing | 0 |
| Solubility: LogP | 1.619 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 33 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 13 | No. of Aromatic Carbocycles | 0 |
| nHetero | 2 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 20 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 11 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 2 | No. of Arom Bond | 0 |
| nHA | 2 | APOL | 33.3099 |
| nHD | 0 | BPOL | 21.8001 |
| QED | 0.658 |
| Synth | 2.721 |
| Natural Product Likeliness | 0.598 |
| NR-PPAR-gamma | 0.003 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0.609 |
| Pgp-sub | 0.008 |
| HIA | 0.01 |
| CACO-2 | -4.607 |
| MDCK | 0.0000219 |
| BBB | 0.978 |
| PPB | 0.763334 |
| VDSS | 0.564 |
| FU | 0.401758 |
| CYP1A2-inh | 0.138 |
| CYP1A2-sub | 0.842 |
| CYP2c19-inh | 0.178 |
| CYP2c19-sub | 0.944 |
| CYP2c9-inh | 0.097 |
| CYP2c9-sub | 0.963 |
| CYP2d6-inh | 0.008 |
| CYP2d6-sub | 0.82 |
| CYP3a4-inh | 0.013 |
| CYP3a4-sub | 0.299 |
| CL | 7.453 |
| T12 | 0.826 |
| hERG | 0.004 |
| Ames | 0.024 |
| ROA | 0.03 |
| SkinSen | 0.114 |
| Carcinogencity | 0.064 |
| EI | 0.96 |
| Respiratory | 0.197 |
| NR-Aromatase | 0.006 |
| Antiviral | No |
| Prediction | 0.730341 |